Investors in XPLR, Centene, Biohaven, and Capricor may pursue legal action for suspected securities fraud.

A lawsuit has been filed against XPLR Infrastructure, Centene Corporation, Biohaven Ltd., and Capricor Therapeutics by stockholders, claiming that the companies provided false and misleading information during specified class periods. Investors who acquired securities in these companies during the outlined class periods may qualify to participate in the lawsuit and request to be appointed as lead plaintiff by September 8, 2025. It is essential for investors in XPLR Infrastructure, Centene Corporation, Biohaven Ltd., and Capricor Therapeutics to remain informed about the ongoing class action lawsuits, as they allege that these companies disseminated inaccurate and deceptive statements during specific class periods, potentially causing significant financial setbacks for investors.

XPLR Infrastructure, LP, formerly known as Nextera Energy Partners, LP, is facing a class action lawsuit alleging that the company encountered difficulties in maintaining its operations as a yieldco and that its financing arrangements were misrepresented. Investors who bought securities in XPLR Infrastructure between September 27, 2023, and January 27, 2025, may be eligible to participate in the lawsuit. The deadline for investors to request to be the lead plaintiff is September 8, 2025.

Centene Corporation is also the target of a class action lawsuit, with accusations that the company provided false and misleading statements concerning its projected revenue outlook and enrollment rates. Investors who purchased securities between December 12, 2024, and June 30, 2025, may meet the criteria to participate in the lawsuit and request to be the lead plaintiff by the same deadline of September 8, 2025.

Biohaven Ltd. is another company entangled in a class action lawsuit where it is alleged that the company disseminated materially false and misleading information regarding its drug candidates, troriluzole, and BHV-7000. Investors who acquired securities between March 24, 2023, and May 14, 2025, might be eligible to join the lawsuit, with the deadline for lead plaintiff petitions set on September 12, 2025.

Capricor Therapeutics, Inc. is facing legal action for purportedly providing false and misleading statements about its lead cell therapy candidate drug, deramiocel. Investors who bought securities between October 9, 2024, and July 10, 2025, may qualify to participate in the lawsuit and request to be the lead plaintiff by the deadline of September 15, 2025.

It is highly recommended that investors explore the class action lawsuit filings and seek advice from legal professionals to ascertain their eligibility and potential involvement in these lawsuits.